JP Patent

JP2025113339A — メニン－ｍｌｌ相互作用の阻害剤

Assigned to Vitae Pharmaceuticals LLC · Expires 2025-08-01 · 1y expired

What this patent protects

【課題】メニン－ＭＬＬ相互作用を阻害する新規薬剤を提供する。【解決手段】式Ｉの化合物又はその医薬的に許容し得るその塩を提供する。【選択図】なし

USPTO Abstract

【課題】メニン－ＭＬＬ相互作用を阻害する新規薬剤を提供する。【解決手段】式Ｉの化合物又はその医薬的に許容し得るその塩を提供する。【選択図】なし

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: JP2025113339A
Jurisdiction: JP
Classification: —
Expires: 2025-08-01
Drug substance claim: No
Drug product claim: No
Assignee: Vitae Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.